You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

T-cell receptor

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Pancreatic Ductal Adenocarcinoma, NSCLC, Colorectal Cancer Trial (AFNT-211)

Not yet recruiting
  • Pancreatic Ductal Adenocarcinoma
  • +4 more
  • (no location specified)
Oct 23, 2023

Non-hodgkin Lymphoma,B Cell Trial in Beijing (Autologous CD19-STAR-T cell, Fludarabine, Cyclophosphamide)

Recruiting
  • Non-hodgkin Lymphoma,B Cell
  • Autologous CD19-STAR-T cell
  • +2 more
  • Beijing, Beijing, China
  • +1 more
Nov 21, 2022

Prostate Carcinoma, Prostate Small Cell Neuroendocrine Carcinoma, Stage III Prostate Cancer AJCC v8 Trial in Seattle (drug,

Not yet recruiting
  • Prostate Carcinoma
  • +3 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Oct 17, 2023

B-Cell Lymphoma, Large B-cell Lymphoma, DLBCL, Nos Genetic Subtypes Trial in New York (19(T2)28z1xx TRAC T cell)

Recruiting
  • B-Cell Lymphoma
  • +4 more
  • 19(T2)28z1xx TRAC T cell
  • New York, New York
    Memorial Sloan Kettering Cancer Center (All Protocol Activities)
Feb 24, 2023

Synovial Sarcoma Trial in Houston (Fludarabine phosphate, NY-ESO-1 TCR/IL-15 NK, Cyclophosphamide)

Not yet recruiting
  • Synovial Sarcoma
  • Fludarabine phosphate
  • +2 more
  • Houston, Texas
    MD Anderson Cancer Center
Oct 9, 2023

Fanconi Anemia, Severe Aplastic Anemia, MDS Trial in Minneapolis (Total Body Irradiation (TBI) (Plan 1), Cyclophosphamide (CY)

Recruiting
  • Fanconi Anemia
  • +2 more
  • Total Body Irradiation (TBI) (Plan 1)
  • +8 more
  • Minneapolis, Minnesota
    Masonic Cancer Center at University of Minnesota
Nov 2, 2022

Blood Cancer Trial (KCAT19 T cells)

Not yet recruiting
  • Blood Cancer
  • KCAT19 T cells
  • (no location specified)
May 20, 2022

Pancreatic Cancer Trial in ShangHai (TCR-T Cells Injection(GB3010 Cells Injection))

Recruiting
  • Pancreatic Cancer
  • TCR-T Cells Injection（GB3010 Cells Injection）
  • ShangHai, Shanghai, China
    Ruijin Hospital Affiliated to Shanghai Jiaotong University Schoo
Sep 19, 2023

Chronic Hepatitis B Trial in Beijing (TCR-T)

Active, not recruiting
  • Chronic Hepatitis B
  • TCR-T
  • Beijing, China
    The Fifth Medical Center of PLA General Hospital
Jun 13, 2023

Hematologic Malignancy, Acute Leukemia, Remission Trial (Fludarabine, Busulfan, Melphalan)

Not yet recruiting
  • Hematologic Malignancy
  • +21 more
  • (no location specified)
Feb 9, 2023

Metastatic Colorectal Adenocarcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Pancreatic Adenocarcinoma Trial in

Not yet recruiting
  • Metastatic Colorectal Adenocarcinoma
  • +5 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Sep 12, 2023

Advanced Solid Tumor Trial in Bethesda, Boston (STAR0602)

Recruiting
  • Advanced Solid Tumor
  • Bethesda, Maryland
  • +1 more
Jan 6, 2023

Lymphoid Leukemia, Acute, Myeloid Malignancy, Plasma Cell Tumor Trial in Miami (T-cell Receptor a/ß Depleted Donor Lymphocyte

Recruiting
  • Lymphoid Leukemia, Acute
  • +2 more
  • T-cell Receptor α/β Depleted Donor Lymphocyte Infusions
  • Miami, Florida
    Miami Cancer Institute at Baptist Health, Inc
May 24, 2022

CAR-T Cell Induced Cardiac Dysfunction: A Prospective Study

Not yet recruiting
  • Lymphoma
  • Chimeric Antigen Receptor
  • (no location specified)
Oct 24, 2023

Malignant Epithelial Tumors Trial in Portland (TCR-transduced T cells, CDX-1140, Pembrolizumab)

Not yet recruiting
  • Malignant Epithelial Neoplasms
  • TCR-transduced T cells
  • +2 more
  • Portland, Oregon
    Providence Portland Medical Center
Apr 22, 2022

Kita-kyushu Lung Cancer Antigen 1, Human Trial run by the NCI (IL-2 (Aldesleukin), Cyclophosphamide, KK-LC-1 TCR)

Recruiting
  • Kita-kyushu Lung Cancer Antigen 1, Human
  • IL-2 (Aldesleukin)
  • +3 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jul 27, 2022

ALLoreactive T-Cell receptOr RePertoire in kidnEy

Recruiting
  • Renal Transplant Rejection
  • +3 more
  • Mixed lymphocyte reaction
  • Vienna, Austria
    Medical university of Vienna
Apr 5, 2022

Prostate Specific Antigens, Prostate Tumors Trial run by the National Cancer Institute (NCI) (TARP peptide vaccine, TARP

Completed
Has Results
  • Prostate Specific Antigens
  • Prostate Neoplasms
  • T-cell receptor alternate reading frame protein (TARP) peptide vaccine
  • T-cell receptor alternate reading frame protein (TARP) dendritic cell vaccine
  • Bethesda, Maryland
    National Institutes of Health Clinical Center, 9000 Rockville Pi
Sep 15, 2022

Kidney Transplant, Kidney Failure, Highly Sensitized Trial in Boston, New York, Philadelphia (Cyclophosphamide, CART-BCMA,

Not yet recruiting
  • Kidney Transplant
  • +2 more
  • Boston, Massachusetts
  • +2 more
Sep 20, 2023

HPV-Associated Cervical Carcinoma, HPV-Related Carcinoma, HPV-Related Malignancy Trial in New Brunswick (Conditioning, E7 TCR-T

Not yet recruiting
  • HPV-Associated Cervical Carcinoma
  • +16 more
  • Conditioning, E7 TCR-T cells, and aldesleukin
  • New Brunswick, New Jersey
    Rutgers Cancer Institute of New Jersey
Jan 17, 2023

Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Solid Tumor Trial in

Suspended
  • Anatomic Stage IV Breast Cancer AJCC v8
  • +8 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
May 23, 2022

Hepatocellular Carcinoma Trial in Guangzhou (TCR-T, No intervention and TCR-T (at crossover))

Completed
  • Hepatocellular Carcinoma
  • TCR-T
  • No intervention and TCR-T (at crossover)
  • Guangzhou, Guangdong, China
    The First Affiliated Hospital, Sun-Yat Sen University
Jun 27, 2022

Multiple Sclerosis, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive Trial in Palo Alto

Not yet recruiting
  • Multiple Sclerosis
  • +2 more
  • KYV-101 anti-CD19 CAR-T cell therapy
  • Standard lymphodepletion regimen
  • Palo Alto, California
    Stanford Multiple Sclerosis Center
Nov 13, 2023

Hematopoietic and Lymphoid Cell Tumor, Malignant Solid Tumor, Metastatic Lung Non-Small Cell Carcinoma Trial in Seattle

Terminated
Has Results
  • Hematopoietic and Lymphoid Cell Neoplasm
  • +12 more
  • Laboratory Biomarker Analysis
  • ROR1 CAR-specific Autologous T-Lymphocytes
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Aug 11, 2022

Lupus Nephritis, Lupus Nephritis - World Health Organization (WHO) Class III, Lupus Nephritis - WHO Class IV Trial in Denver,

Recruiting
  • Lupus Nephritis
  • +2 more
  • KYV-101 anti-CD19 CAR-T cell therapy
  • Standard lymphodepletion regimen
  • Denver, Colorado
  • +1 more
Jul 7, 2023